基于脂肪酸衍生干细胞的抗炎性膜因子调节,用于治疗炎症性肠病
Naeun Park1, Kyoung Sub Kim2, Chun Gwon Park3
1Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Republic of Korea; Department of Biomedical-Chemical Engineering, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 14662, Republic of Korea.
概括
在炎症性肠病 (IBD) 模型中,改造的脂肪衍生干细胞 (ADSC) 显示出更好的生存率和治疗效果. 光激活的ARPC细胞通过调节免疫反应来减少炎症并促进愈合.
科学领域:
- 再生医学是一种再生医学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 干细胞疗法对由于免疫调节效应导致的炎症性疾病有前途.
- 在炎症组织中的干细胞生存和疗效方面,仍然存在挑战.
- 脂肪基衍生干细胞 (ADSC) 是基于细胞的疗法的潜在来源.
研究的目的:
- 在炎症环境中设计ADSC以提高活力和治疗因子分泌.
- 开发一种在现场追踪和激活干细胞的方法.
- 评估工程ADSCs在治疗炎症性肠病 (IBD) 的疗效.
主要方法:
- 合成了一种阿尔金-甘氨酸-酸-多 (乙烯糖醇) -e6联合物 (RPC).
- 与ADSC结合RPC,以创建RPC标记的ADSC (ARPC),用于RGD-整合素相互作用和可视化.
- 在体外和体内IBD模型中评估ARPC活力,膜因子分泌和免疫调节效应.
- 利用RNA测序来分析受ARPC治疗影响的细胞通路.
主要成果:
- 在光激活后,ARPC表现出增强的活力和膜因子分泌.
- RNA测序揭示了促进血管生成,DNA修复和外体分泌的途径,同时降低了炎症的调节.
- 在体内IBD模型显示,ARPC治疗减少了炎症,保持了结肠结构,并增加了调节性T细胞.
- ARPC选择性地定位到炎症部位,表明有针对性的治疗交付.
结论:
- 工程ARPC细胞为IBD等炎症性疾病提供了一个有前途的治疗策略.
- 在炎症微环境中,ARPC增强了干细胞的生存和功能.
- 光激活的ARPC有针对性的输送调节了免疫反应,创造了一个抗炎环境.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
01:28Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123